Literature DB >> 16888615

Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2.

R R Einerson1, M E Law, H E Blair, P J Kurtin, R F McClure, R P Ketterling, H C Flynn, A Dogan, E D Remstein.   

Abstract

Detection of translocations involving MYC at 8q24.1 in B-cell lineage malignancies (BCL) is important for diagnostic and prognostic purposes. However, routine detection of MYC translocations is often hampered by the wide variation in breakpoint location within the MYC region, particularly when a gene other than IGH, such as IGK or IGL, is involved. To address this issue, we developed and validated four fluorescence in situ hybridization (FISH) probes: two break apart probes to detect IGK and IGL translocations, and two dual-color, dual-fusion FISH (D-FISH) probes to detect IGK-MYC and IGL-MYC. MYC rearrangements (four IGK-MYC, 12 IGL-MYC and four unknown partner gene-MYC) were correctly identified in 20 of 20 archival BCL specimens known to have MYC rearrangements not involving IGH. Seven specimens, all of which lacked MYC rearrangements using a commercial IGH/MYC D-FISH probe, were found to have 8q24 breakpoints within a cluster region >350-645 kb 3' from MYC, provisionally designated as Burkitt variant rearrangement region 2 (BVR2). FISH is a useful ancillary tool in identifying MYC rearrangements. In light of the discovery of the distally located BVR2 breakpoint cluster region, it is important to use MYC FISH probes that cover a breakpoint region at least 1.0 Mb 3' of MYC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888615     DOI: 10.1038/sj.leu.2404340

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Authors:  Itziar Salaverria; Idoia Martin-Guerrero; Rabea Wagener; Markus Kreuz; Christian W Kohler; Julia Richter; Barbara Pienkowska-Grela; Patrick Adam; Birgit Burkhardt; Alexander Claviez; Christine Damm-Welk; Hans G Drexler; Michael Hummel; Elaine S Jaffe; Ralf Küppers; Christine Lefebvre; Jasmin Lisfeld; Markus Löffler; Roderick A F Macleod; Inga Nagel; Ilske Oschlies; Maciej Rosolowski; Robert B Russell; Grzegorz Rymkiewicz; Detlev Schindler; Matthias Schlesner; René Scholtysik; Carsten Schwaenen; Rainer Spang; Monika Szczepanowski; Lorenz Trümper; Inga Vater; Swen Wessendorf; Wolfram Klapper; Reiner Siebert
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

2.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Authors:  Mamta Gupta; Matthew J Maurer; Linda E Wellik; Mark E Law; Jing Jing Han; Nazan Ozsan; Ivana N Micallef; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

3.  False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.

Authors:  Rebecca L King; Ellen D McPhail; Reid G Meyer; George Vasmatzis; Kathryn Pearce; James B Smadbeck; Rhett P Ketterling; Stephanie A Smoley; Patricia T Greipp; Nicole L Hoppman; Jess F Peterson; Linda B Baughn
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

4.  Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.

Authors:  Alexandra Valera; Samantha Epistolio; Lluis Colomo; Alice Riva; Olga Balagué; Ivan Dlouhy; Alexandar Tzankov; Marco Bühler; Eugenia Haralambieva; Elias Campo; Davide Soldini; Luca Mazzucchelli; Vittoria Martin
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

5.  Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.

Authors:  Daniel P Cassidy; Jennifer R Chapman; Rafael Lopez; Kyle White; Yao-Shan Fan; Carmen Casas; Eric A Severson; Francisco Vega
Journal:  Am J Clin Pathol       Date:  2020-02-08       Impact factor: 2.493

6.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Authors:  Nathalie A Johnson; Kerry J Savage; Olga Ludkovski; Susana Ben-Neriah; Ryan Woods; Christian Steidl; Martin J S Dyer; Reiner Siebert; John Kuruvilla; Richard Klasa; Joseph M Connors; Randy D Gascoyne; Douglas E Horsman
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

7.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

Review 8.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

9.  High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Authors:  Lauren C Chong; Susana Ben-Neriah; Graham W Slack; Ciara Freeman; Daisuke Ennishi; Anja Mottok; Brett Collinge; Pau Abrisqueta; Pedro Farinha; Merrill Boyle; Barbara Meissner; Robert Kridel; Alina S Gerrie; Diego Villa; Kerry J Savage; Laurie H Sehn; Reiner Siebert; Ryan D Morin; Randy D Gascoyne; Marco A Marra; Joseph M Connors; Andrew J Mungall; Christian Steidl; David W Scott
Journal:  Blood Adv       Date:  2018-10-23

10.  Atypical rearrangement involving 3'-IGH@ and a breakpoint at least 400 Kb upstream of an intact MYC in a CLL patient with an apparently balanced t(8;14)(q24.1;q32) and negative MYC expression.

Authors:  Ina Amarillo; Peter H Bui; Sibel Kantarci; Nagesh Rao; Brit S Shackley; Rolando García; Carlos A Tirado
Journal:  Mol Cytogenet       Date:  2013-02-01       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.